These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


131 related items for PubMed ID: 1697660

  • 1. Pyridostigmine potentiates L-dopa- but not arginine- and galanin-induced growth hormone secretion in children.
    Ghigo E, Bellone J, Imperiale E, Arvat E, Mazza E, Valetto MR, Boffano GM, Cappa M, Loche S, De Sanctis C.
    Neuroendocrinology; 1990 Jul; 52(1):42-5. PubMed ID: 1697660
    [Abstract] [Full Text] [Related]

  • 2. Evidence for involvement of endogenous somatostatin in the galanin-induced growth hormone secretion in children.
    Loche S, Vista N, Ghigo E, Vannelli S, Arvat E, Benso L, Corda R, Cella SG, Müller EE, Pintor C.
    Pediatr Res; 1990 Apr; 27(4 Pt 1):405-7. PubMed ID: 1692988
    [Abstract] [Full Text] [Related]

  • 3. Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine.
    Ghigo E, Bellone J, Mazza E, Imperiale E, Procopio M, Valente F, Lala R, De Sanctis C, Camanni F.
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):763-7. PubMed ID: 1974484
    [Abstract] [Full Text] [Related]

  • 4. Interactions of galanin and arginine on growth hormone, prolactin, and insulin secretion in man.
    Ghigo E, Maccario M, Arvat E, Valetto MR, Valente F, Nicolosi M, Mazza E, Martina V, Cocchi D, Camanni F.
    Metabolism; 1992 Jan; 41(1):85-9. PubMed ID: 1371576
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the potentiating effect of pyridostigmine, arginine and propranolol on the GHRH-induced GH release in short children.
    Bellone J, Ghigo E, Procopio M, Arvat E, Valente F, Boffano GM, Maccario M, Dentelli P, Camanni F.
    Panminerva Med; 1993 Mar; 35(1):1-4. PubMed ID: 8316397
    [Abstract] [Full Text] [Related]

  • 6. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [Abstract] [Full Text] [Related]

  • 7. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 8. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E, Imperiale E, Boffano GM, Mazza E, Bellone J, Arvat E, Procopio M, Goffi S, Barreca A, Chiabotto P.
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [Abstract] [Full Text] [Related]

  • 9. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G, Grugni G, Morabito F.
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [Abstract] [Full Text] [Related]

  • 10. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.
    Arvat E, Cappa M, Casanueva FF, Dieguez C, Ghigo E, Nicolosi M, Valcavi R, Zini M.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):374-7. PubMed ID: 8432781
    [Abstract] [Full Text] [Related]

  • 11. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

  • 12. Low dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children.
    Bellone J, Bartolotta E, Cardinale G, Arvat E, Cherubini V, Aimaretti G, Maccario M, Mucci M, Camanni F, Ghigo E.
    J Endocrinol Invest; 1993 Feb; 16(7):521-5. PubMed ID: 8227981
    [Abstract] [Full Text] [Related]

  • 13. The effects of galanin on growth hormone secretion in children of normal and short stature.
    Loche S, Cella SG, Puggioni R, Stabilini L, Pintor C, Müller EE.
    Pediatr Res; 1989 Oct; 26(4):316-9. PubMed ID: 2477790
    [Abstract] [Full Text] [Related]

  • 14. Growth hormone secretion in Alzheimer's disease: studies with growth hormone-releasing hormone alone and combined with pyridostigmine or arginine.
    Ghigo E, Nicolosi M, Arvat E, Marcone A, Danelon F, Mucci M, Franceschi M, Smirne S, Camanni F.
    Dementia; 1993 Oct; 4(6):315-20. PubMed ID: 8136894
    [Abstract] [Full Text] [Related]

  • 15. GH secretion in Prader-Labhard-Willi syndrome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine.
    Beccaria L, Bosio L, Sanzari A, Aimaretti G, Ghigo E, Chiumello G.
    J Pediatr Endocrinol Metab; 1996 Oct; 9(6):577-83. PubMed ID: 9004172
    [Abstract] [Full Text] [Related]

  • 16. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
    Arvat E, Gianotti L, Ragusa L, Valetto MR, Cappa M, Aimaretti G, Ramunni J, Grottoli S, Camanni F, Ghigo E.
    Dementia; 1996 Oct; 7(5):288-92. PubMed ID: 8872421
    [Abstract] [Full Text] [Related]

  • 17. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa.
    Ghigo E, Arvat E, Gianotti L, Nicolosi M, Valetto MR, Avagnina S, Bellitti D, Rolla M, Müller EE, Camanni F.
    Biol Psychiatry; 1994 Nov 15; 36(10):689-95. PubMed ID: 7880938
    [Abstract] [Full Text] [Related]

  • 18. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.
    Ghigo E, Bellone J, Aimaretti G, Bellone S, Loche S, Cappa M, Bartolotta E, Dammacco F, Camanni F.
    J Clin Endocrinol Metab; 1996 Sep 15; 81(9):3323-7. PubMed ID: 8784091
    [Abstract] [Full Text] [Related]

  • 19. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998 Sep 15; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

  • 20. Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children.
    Kirk JM, Ross RJ, Trainer PJ, Froud AL, Davies SC, Savage MO, Besser GM.
    Clin Endocrinol (Oxf); 1991 May 15; 34(5):407-11. PubMed ID: 2060150
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.